CUNY SPH and NYC Health Department receive grant to study long-acting injectables for HIV

NewsGuard 100/100 Score

The National Institute of Mental Health (NIMH) has awarded the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the New York City Department of Health and Mental Hygiene (NYC Health Department) a thirty month grant to support long-acting injectable antiretroviral therapy access, uptake, and adherence among people with HIV enrolled in the Ryan White HIV/AIDS Program (hereafter "Ryan White").

The APPLI study (Assessing Perceptions and Preferences around Long-acting Injectables) will be led by CUNY SPH Distinguished Professor Denis Nash and Dr. Mary Irvine, Director of the NYC Health Department's HIV Care and Treatment Research and Evaluation Unit, in partnership with six Ryan White Part A-funded medical case management provider agencies in New York City and the Tri-County area, which includes Westchester, Putnam, and Rockland counties.

This project aligns with the "Treatment" pillar from the U.S. Department of Health and Human Services Ending the HIV Epidemic (EHE) initiative and with two of the National Institutes of Health's priorities: reducing health disparities and implementation research on new HIV treatments. Although HIV treatment advances have improved health and survival for people living with HIV in New York, racial/ethnic, age-related, geographic, and other disparities in viral suppression remain.

Long-acting injectable antiretroviral therapies are a potential game-changer for people living with HIV who have struggled with adherence to daily oral medication regimens."

Denis Nash, Executive Director, CUNY Institute for Implementation Science in Population Health (CUNY ISPH)

In January 2021, the United States Food and Drug Administration approved one long-acting antiretroviral injectable drug combination (Cabenuva), currently limited to people with HIV who are already virally suppressed. Moreover, clinical trials of the regimen that demonstrated efficacy only included people who were stable on daily oral antiretroviral therapy regimens, and not those who struggle with adherence and thus may benefit most from the new treatment modality. Anticipating expansion of eligibility to include more people living with HIV, the APPLI study will use routine reporting on clients and services, and both qualitative data collection and discrete choice experiments, to understand drivers of engagement in various antiretroviral therapy delivery and adherence support strategies in New York's Ryan White Part A medical case management programs. Based on this formative work, the study team and provider partners (both clinical and non-clinical) will pilot service strategies to integrate long-acting injectables as a treatment option, and explore how best to support adherence, and ultimately EHE impact, in real-world Ryan White HIV care settings.

"We really don't yet know how feasible or acceptable this may be as an option, both to the clients and their providers," says Nash. "But it is critically important to find out quickly, to optimize the public health impact of these advances."

Findings from this timely study will be relevant to the equitable, effective, and sustainable advancement of the next generation of therapeutic interventions capable of improving HIV care among people living with HIV who have been unable to achieve viral suppression using previously available therapies.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vaccine candidate spurs elusive type of broadly neutralizing HIV antibodies